Clinical trialNCT00751231CompletedPhase 2Interventional

A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI

SponsorPortola PharmaceuticalsEnrollment652Percutaneous Coronary Intervention

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multi-center, randomized, double-blind, triple-dummy, clopidogrel-controlled study of IV and oral PRT060128 compared to clopidogrel in patients undergoing non-urgent (including elective) PCI. After diagnostic angiography, patients scheduled for non-urgent PCI will be randomized to clopidogrel or to one of three dose levels of PRT060128.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Robert C Welsh, MD
University of Alberta
Principal Investigator
clinicaltrials.gov ↗
Robert Harrington, MD
Duke University
Study ChairKOL profile →
clinicaltrials.gov ↗
Sunil V Rao, MD
Duke University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

59 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Austria

Portola Investigational Site
Graz, Austria
Portola Investigational Site
Vienna, Austria

Canada

Portola Investigational Site
Calgary, Alberta, Canada
Portola Investigational Site
Edmonton, Alberta, Canada
Portola Investigational Site
Vancouver, British Columbia, Canada
Portola Investigational Site
St. John's, Newfoundland and Labrador, Canada
Portola Investigational Site
Newmarket, Ontario, Canada
Portola Investigational Site
Toronto, Ontario, Canada

Germany

Portola Investigational Site
Bad Oeynhausen, Germany
Portola Investigational Site
Bad Rothenfelde, Germany
Portola Investigational Site
Berlin, Germany
Portola Investigational Site
Bernau, Germany
Portola Investigational Site
Dachau, Germany
Portola Investigational Site
Dortmund, Germany
Portola Investigational Site
Dresden, Germany
Portola Investigational Site
Göttingen, Germany
Portola Investigational Site
Halle, Germany
Portola Investigational Site
Hanover, Germany
Portola Investigational Site
Heidelberg, Germany
Portola Investigational Site
Kassel, Germany
Portola Investigational Site
Kiel, Germany
Portola Investigational Site
Langen, Germany
Portola Investigational Site
Ludwigshafen, Germany
Portola Investigational Site
Lübeck, Germany
Portola Investigational Site
Mainz, Germany
Portola Investigational Site
Munich, Germany
Portola Investigational Site
Mönchengladbach, Germany
Portola Investigational Site
Neuss, Germany
Portola Investigational Site
Rostock, Germany
Portola Investigational Site
Schwalmstadt, Germany
Portola Investigational Site
Traunstein, Germany
Portola Investigational Site
Trier, Germany
Portola Investigational Site
Witten, Germany
Portola Investigational Site
Wuppertal, Germany

Poland

Portola Investigational Site
Bydgoszcz, Poland
Portola Investigational Site
Gdansk, Poland
Portola Investigational Site
Lodz, Poland
Portola Investigational Site
Lublin, Poland
Portola Investigational Site
Szczecin, Poland
Portola Investigational Site
Warsaw, Poland

19 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PRT060128Clopidogrel →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2008
Primary completion: 30 Apr 2010
Completion: 30 Apr 2010
Last update posted: 8 Aug 2023
Registered enrollment: 652
Registry id: NCT00751231

Cross-registrations

EU-CTR / CTIS (EudraCT)2008-001352-51

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.